Italia markets close in 4 hours 29 minutes
FTSE MIB
34.771,89 +279,48 (+0,81%) Dow Jones
38.686,32 +574,82 (+1,51%) Nasdaq
16.735,02 -2,08 (-0,01%) Nikkei 225
38.923,03 +435,13 (+1,13%) Petrolio
76,88 -0,11 (-0,14%) Bitcoin EUR
63.607,96 +1.369,93 (+2,20%)
NVCR Dec 2025 25.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
In data: 10:37AM EDT. Mercato aperto.
| Chiusura precedente | 7,40 |
| Aperto | 7,50 |
| Denaro | 0,00 |
| Domanda | 0,00 |
| Prezzo d'esercizio | 25,00 |
| Scadenza | 2025-12-19 |
| Min-Max giorno | 7,40 - 7,50 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | N/D |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.